Elevated lipocalin 2 (LCN2) levels has also been reported in tissue- and urine samples from patients with invasive breast cancer [37] and is proposed as a noninvasive biomarker for advanced breast cancer. The gene discussed is LCN2; the disease is breast carcinoma.